2017
Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo.
Kang K, Schrump D, Thomas A, Schalper K, Saunthararajah Y, Velcheti V. Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo. Journal Of Clinical Oncology 2017, 35: 11552-11552. DOI: 10.1200/jco.2017.35.15_suppl.11552.Peer-Reviewed Original ResearchT cellsC57/BL6 miceAbsolute lymphocyte countAnti-PD1 therapyRegulatory T cellsTumor-Infiltrating LymphocytesImmune memory effectTumor-bearing miceDNMT1 depletionMost NSCLCNSCLC responsePharmacologic rationaleG-MDSCSolid cancer tissuesImmunotherapeutic effectsLymphocyte countMedian survivalIFNγ expressionInfiltrating lymphocytesSurvival improvementMAGE-A3BL6 miceLung invasionAntigen presentationMAGE-A1
2016
Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research 2016, 18: 78. PMID: 27473061, PMCID: PMC4966732, DOI: 10.1186/s13058-016-0737-x.Peer-Reviewed Original ResearchConceptsIntraclass correlation coefficientQuantitative immunofluorescenceBreast cancerSame cancerSingle biopsyMultiplexed quantitative immunofluorescenceTumor-infiltrating lymphocytesPotential predictive markerPrimary breast carcinomaCytokeratin-positive epithelial cellsCD20-positive lymphocytesCD8 levelsLymphocyte scoreQIF scoresLymphocyte countLymphocyte subpopulationsMultiple biopsiesSubpopulation countsPredictive markerPrognostic informationBreast carcinomaBiopsyB lymphocytesCD3Breast tumors